Literature DB >> 6175461

Evaluation of the human interferon system in viral disease.

S Levin, T Hahn.   

Abstract

The interferon (IFN) system in man regulates viral replication, cell multiplication and immune functions. Its action against viruses takes place in two stages. The first is the production of IFN by cells following stimulation by a variety of IFN inducers including viruses, and the second is the action of this IFN on other cells inducing in them an antiviral state which prevents replication of infecting viruses. A series of assays is described which evaluates these different parameters of the antiviral IFN system. An attempt was made to correlate between IFN production and cell response to IFN on the one hand, and clinical status on the other. Results show that healthy persons have little or no IFN in the blood (mean less than 4 units/ml), and that in 94% their PBMC are not in an antiviral state. On the other hand, patients with acute viral diseases have significantly increased levels of IFN in their blood (mean 150 +/- 284 units/ml), and in 70% their cells are in an antiviral state. In some seriously ill patients with viral disease, the IFN system was found to be functionally deficient and treatment with human leucocyte IFN rapidly changed this. It is concluded that the examination of several biological parameters of the IFN system including the intracellular antiviral state induced by IFN is necessary in order to better evaluate this antiviral system. This will enable the clinician to obtain optimal pharmacokinetic information for determining which cases are most likely to respond to IFN therapy, and help to monitor the efficacy of this treatment.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6175461      PMCID: PMC1536310     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  7 in total

Review 1.  Clinical trials with exogenous interferon: summary of a meeting.

Authors:  J K Dunnick; G J Galasso
Journal:  J Infect Dis       Date:  1979-01       Impact factor: 5.226

2.  Specificity and reversibility of interferon ganglioside interaction.

Authors:  F Besancon; H Ankel; S Basu
Journal:  Nature       Date:  1976-02-19       Impact factor: 49.962

3.  Immune competence of newborn lymphocytes.

Authors:  Z T Handzel; S Levin; Z Dolphin; M Schlesinger; T Hahn; Y Altman; B Schechter; A Shneyour; N Trainin
Journal:  Pediatrics       Date:  1980-03       Impact factor: 7.124

Review 4.  Virus infections of lympho-reticular cells and auto-immune diseases.

Authors:  A M Denman; B K Pelton; D Appleford; M Kinsley
Journal:  Transplant Rev       Date:  1976

5.  General considerations of the interferon system.

Authors:  S Baron; F Dianzani
Journal:  Tex Rep Biol Med       Date:  1977

6.  Role of interferon in augmentation of natural and antibody-dependent cell-mediated cytotoxicity.

Authors:  R B Herberman; J Y Djeu; J R Ortaldo; H T Holden; W H West; G D Bonnard
Journal:  Cancer Treat Rep       Date:  1978-11

7.  Production of immune and viral interferon by lymphocytes of newborn infants.

Authors:  T Hahn; S Levin; Z T Handzel
Journal:  Isr J Med Sci       Date:  1980-01
  7 in total
  18 in total

1.  Increased activity of oligo-2',5'-adenylate synthetase in Down's syndrome and epilepsy.

Authors:  N Fujii; K Oguma; M Fujii; R Fukatsu; N Takahata; M Kitabatake
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

2.  Induction and measurement of 2',5'-oligoadenylate synthetase in Madin-Darby bovine kidney cells and in cattle.

Authors:  E C Short; R W Fulton
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

3.  Natural killer cells in viral arthritis.

Authors:  J G Aaskov; D A Dalglish; J J Harper; J F Douglas; M D Donaldson; P J Hertzog
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

4.  Immune impairments and antibodies to HTLVIII/LAV in asymptomatic male homosexuals in Israel: relevance to the risk of acquired immune deficiency syndrome (AIDS).

Authors:  Z Bentwich; C Saxinger; Z Ben-Ishay; R Burstein; Y Berner; M Pecht; N Trainin; S Levin; Z T Handzel
Journal:  J Clin Immunol       Date:  1987-09       Impact factor: 8.317

5.  Influence of alpha-interferon therapy on blood lymphoid cells. Studies on antibody production, mixed lymphocyte culture response, mitogen responsiveness and 2'-5'oligoadenylate synthetase activity.

Authors:  S Einhorn; P Ling; N Einhorn; H Strander; J Wasserman
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

6.  Interferon deficiency syndrome.

Authors:  S Levin; T Hahn
Journal:  Clin Exp Immunol       Date:  1985-05       Impact factor: 4.330

7.  (2'-5') oligo adenylate synthetase activity in leucocytes of patients with inflammatory bowel disease.

Authors:  R Stalnikowicz; K Goder; F Karmeli; C Fiocchi; D Rachmilewitz
Journal:  Gut       Date:  1985-06       Impact factor: 23.059

8.  Interferon in acute viral infections.

Authors:  S Levin
Journal:  Eur J Pediatr       Date:  1983-03       Impact factor: 3.183

9.  Pilot study of recombinant interferon alpha-2a for treatment of infants with bronchiolitis induced by respiratory syncytial virus.

Authors:  J Portnoy; R Hicks; F Pacheco; L Olson
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

10.  Interferon system in acute transient synovitis.

Authors:  E Leibowitz; S Levin; J Torten; R Meyer
Journal:  Arch Dis Child       Date:  1985-10       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.